| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC | Director | Option to purchase Ordinary Shares | 1.14M | Jul 1, 2024 | Direct | ||
| TCR2 THERAPEUTICS INC. | Director | Stock Option (Right to Buy) | 0 | $0.74 | Jun 1, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | Jul 1, 2024 | 1 | $0 | 4 | Jul 1, 2024 | Director |
| ADAP | Adaptimmune Therapeutics PLC | Jul 5, 2023 | 3 | $0 | 4 | Jul 5, 2023 | Director |
| ADAP | Adaptimmune Therapeutics PLC | Jul 3, 2023 | 1 | $0 | 4 | Jul 3, 2023 | Director |
| ADAP | Adaptimmune Therapeutics PLC | Jun 1, 2023 | 0 | $0 | 3 | Jun 1, 2023 | Director |
| TCRR | TCR2 THERAPEUTICS INC. | Jun 1, 2023 | 3 | $0 | 4 | Jun 1, 2023 | Director |
| TCRR | TCR2 THERAPEUTICS INC. | Dec 15, 2022 | 1 | $0 | 4 | Dec 19, 2022 | Director |
| TCRR | TCR2 THERAPEUTICS INC. | Dec 9, 2021 | 1 | $0 | 4 | Dec 10, 2021 | Director |
| TCRR | TCR2 THERAPEUTICS INC. | Aug 25, 2021 | 1 | $0 | 4 | Aug 26, 2021 | Director |
| TCRR | TCR2 THERAPEUTICS INC. | Aug 25, 2021 | 0 | $0 | 3 | Aug 26, 2021 | Director |